Your browser doesn't support javascript.
loading
An AI Approach to Identifying Novel Therapeutics for Rheumatoid Arthritis.
Rajan, Jency R; McDonald, Stephen; Bjourson, Anthony J; Zhang, Shu-Dong; Gibson, David S.
Afiliação
  • Rajan JR; Personalised Medicine Centre, School of Medicine, Ulster University, Londonderry BT47 6SB, UK.
  • McDonald S; Rheumatology Department, Altnagelvin Hospital, Western Health and Social Care Trust, Londonderry BT47 6SB, UK.
  • Bjourson AJ; Personalised Medicine Centre, School of Medicine, Ulster University, Londonderry BT47 6SB, UK.
  • Zhang SD; Personalised Medicine Centre, School of Medicine, Ulster University, Londonderry BT47 6SB, UK.
  • Gibson DS; Personalised Medicine Centre, School of Medicine, Ulster University, Londonderry BT47 6SB, UK.
J Pers Med ; 13(12)2023 Nov 23.
Article em En | MEDLINE | ID: mdl-38138860
ABSTRACT
Rheumatoid arthritis (RA) is a chronic autoimmune disorder that has a significant impact on quality of life and work capacity. Treatment of RA aims to control inflammation and alleviate pain; however, achieving remission with minimal toxicity is frequently not possible with the current suite of drugs. This review aims to summarise current treatment practices and highlight the urgent need for alternative pharmacogenomic approaches for novel drug discovery. These approaches can elucidate new relationships between drugs, genes, and diseases to identify additional effective and safe therapeutic options. This review discusses how computational approaches such as connectivity mapping offer the ability to repurpose FDA-approved drugs beyond their original treatment indication. This review also explores the concept of drug sensitisation to predict co-prescribed drugs with synergistic effects that produce enhanced anti-disease efficacy by involving multiple disease pathways. Challenges of this computational approach are discussed, including the availability of suitable high-quality datasets for comprehensive analysis and other data curation issues. The potential benefits include accelerated identification of novel drug combinations and the ability to trial and implement established treatments in a new index disease. This review underlines the huge opportunity to incorporate disease-related data and drug-related data to develop methods and algorithms that have strong potential to determine novel and effective treatment regimens.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article